364
Views
5
CrossRef citations to date
0
Altmetric
Research Articles

Development and evaluation of controlled release ibuprofen matrix tablets by direct compression technique

, &
Pages 1-11 | Received 19 Aug 2009, Accepted 03 Nov 2009, Published online: 24 May 2010

References

  • Nada A, Al-Saidan S, Mueller B. Improving the physical and chemical properties of ibuprofen. Pharm Tech 2005;29(11).
  • Potthast H, Dressman J, Junginger H, Midha K, Oeser H, Shah P, Vogelpoel H, Barends D. Biowaiver monographs for immediate release solid oral dosage forms: Ibuprofen. J Pharm Sci 2005;94(10):2121–2131.
  • Doshi A, Deshpande S. In vivo pharmacokinetic studies of prodrugs of ibuprofen. Indian J Pharm Sci 2007;69(6):824–827.
  • Geisslinger G, Stock KP, Bach GL, Loew D, Brune K. Pharmacological differences between R(-)- and S(+) ibuprofen. Agents Actions 1989;27(3–4):455–457.
  • Brittain H. Analytical profiles of drug substances and excipients. Milford, NJ: Center of Pharmaceutical Physics; 2001;27:265–296.
  • Rafiee-Tehrani M, Sadegh-shobeiri. Effect of various polymers on formulation of controlled release (CR) ibuprofen tablets by fluid bed technique. Drug Dev Ind Pharm 1995;21(10): 1193–1202.
  • Palmieri GF, Lovato D, Martelli S. New controlled-release ibuprofen tablets. Drug Dev Ind Pharm 1999;25(5):671–677.
  • Reza S, Quadir M, Haider S. Comparative evaluation of plastic, hydrophobic and hydrophilic polymers as matrices for controlled-release drug delivery. J Pharm Sci 2003;6(2):274–291.
  • Merchant H, Shoaib M, Tazeen J, Yousuf R. Once-daily tablet formulation and in vitro release evaluation of cefpodoxime using hydroxypropyl methylcellulose: A technical note. AAPS PharmSciTech 2006; 7(3): Article 78.
  • Ceballos A, Cirri M, Maestrelli F, Corti G, Mura P. Influence of formulation and process variables on in vitro release of theophylline from directly-compressed Eudragit matrix tablets. Il Pharamco 2005;60:913–918.
  • Fujimori J, Yoshihashi Y, Yonemochi E, Terada K. Application of Eudragit RS to thermo-sensitive drug delivery systems: II. Effect of temperature on drug permeability through membrane consisting of Eudragit RS/PEG 400 blend. J Control Rel 2005;102:49–57.
  • Brannon-Peppas L. Polymers in controlled drug delivery. Med Plastics Biomaterials 1997;4(6):34–45.
  • Limmatvapirat S, Limmatvapirat C, Puttipipatkhachorn S, Nunthanid J, Luangtana-anan M, Sriamornsak P. Modulation of drug release kinetics of shellac-based matrix tablets by in-situ polymerization through annealing process. Eur J Pharm Biopharm 2008;69(3):1004–1013.
  • Khan G, Zhu J. Ibuprofen release kinetics from controlled-release tablets granulated with aqueous polymeric dispersion of ethyl cellulose II: Influence of several parameters and coexcipients. J Control Rel 1998; 56:127–134.
  • Khan G, Zhu J. Studies on drug release kinetics from ibuprofen-carbomer hydrophilic matrix tablets: Influence of co-excipients on release rate of the drug. J Control Rel 1999;57(2): 197–203.
  • Kranz H, Wagner T. Effects of formulation and process variables on the release of a weakly basic drug from single unit extended release formulations. Eur J Pharm Biopharm 2006;62:70–76.
  • Cox P, Khan K, Munday D, Sujja-areevath J. Development and evaluation of a multiple-unit oral sustained release dosage form for S (+)-ibuprofen: Preparation and release kinetics. Int J Pharm 1999;193(1):73–84.
  • Ford J, Rubinstein M, Hogan J. Formulation of sustained release promethazine hydrochloride tablets using hydroxypropylmethylcellulose matrices. Int J Pharm 1985;24:327–338.
  • Velasco V, Ford L, Rowe P, Ali R. Siahboomi R. Influence of drug: hydroxypropylmethylcellulose ratio, drug and polymer particle size and compression force on the release of diclofenac sodium from HPMC tablets. J Control Rel 1999;57(1):75–85.
  • Fassihi A. Kinetics of drug release from solid matrices: Effect of compaction pressure. Int J Pharm 1987;37:119–125.
  • Eudragit Application Guidelines. 10th ed. Darmstadt, Germany: Evonik Industries AG; 2008.
  • Chien YW, Lin S. Optimisation of treatment by applying programmable rate-controlled drug delivery technology. Clin Pharmacokinet 2002;41(15):1267–1299.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.